HR Collard

Reduction in Non-Elective Respiratory-Related Hospitalizations in Patients Treated With Pirfenidone: Pooled Analyses from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis

Ulrich Costabel, JJ Swigris, Brett Ley, John L. Stauffer et autres

Rationale: Patients with idiopathic pulmonary fibrosis (IPF) are frequently hospitalized for a variety of reasons. Respiratory-related hospitalizations may occur because of acute exacerbations of IPF, respiratory tract infections, respiratory failure and other causes. Regardless of cause, respiratory-related hospitalizations have been linked to …

de, us (code pays fourni par la source)

House of cards? Testing fundamental assumptions in idiopathic pulmonary fibrosis epidemiology - eScholarship

Brett Ley, HR Collard

Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis

Ulrich Costabel, Luca Richeldi, Arata Azuma, Yoshikazu Inoue et autres

Background: The two replicate randomized, double-blind, placebo-controlled, 52-week Phase III INPULSIS™ trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in mL/year, …

de, gb, jp, us, fr, fi, mx (code pays fourni par la source)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)

Ulrich Costabel, Luca Richeldi, RM du Bois, Ganesh Raghu et autres

Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. Methods: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 [NCT01335464] and INPULSIS-2 [NCT01335477]) to evaluate the efficacy and safety of 150 mg of …

de, gb, us, jp, fr, kr, ca, mx, fi (code pays fourni par la source)

“ERS/ATS Task Force onUndifferentiated Forms of CTD-ILD”. An official European RespiratorySociety/American Thoracic Society research statement: interstitial pneumonia withautoimmunefeatures

Allen Fischer, KM Antoniou, KK Brown, Jacques Cadranel et autres

Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack …

The Effect Of Bronchodilators On Forced Vital Capacity In Patients With Idiopathic Pulmonary Fibrosis

Deborah Assayag, Eric Vittinghoff, Christopher J. Ryerson, Elisabetta Cocconcelli et autres

Longitudinal lung function in idiopathic NSIP: what are we missing?

Hua Yun Chen, Ana Villar Gómez, Anthony K. Shum, HR Collard

To the Editors: In a recent article, Park et al. 1 described the clinical course and changes in lung function of 83 patients classified as idiopathic nonspecific interstitial pneumonia (NSIP). Park et al. 1 found that 81% of patients with fibrotic NSIP …

Clinical, Physiologic, and Radiographic Comparison of Patients with Undifferentiated Connective Tissue Disease-ILD and Scleroderma-ILD.

BW Kinder, Francis X. McCormack, HR Collard, P.J. Wolters et autres